Search

Perez-Londono, A., F. Ramos, A. Fleishman, S. Kaul, R. Korets, M. Johnson, A. F. Olumi, L. Tsai, and B. Gershman. 2025. Predicting Cancer Detection Rates from Multiparametric Prostate MRI Beyond the PI-RADS Classification System.

San Francisco, I. F., W. C. DeWolf, S. Rosen, M. Upton, and A. F. Olumi. 2003. Extended Prostate Needle Biopsy Improves Concordance of Gleason Grading Between Prostate Needle Biopsy and Radical Prostatectomy.

Kuten, A., A. Olumi, J. Goldsmith, R. A. Monahan-Earley, A. M. Dvorak, and E. M. Genega. 2004. Pathologic Quiz Case. A Symptomatic Renal Tumor. Juxtaglomerular Cell Tumor.

San Francisco, I. F., M. M. Regan, A. F. Olumi, and W. C. DeWolf. 2004. Percent of Cores Positive for Cancer Is a Better Preoperative Predictor of Cancer Recurrence After Radical Prostatectomy Than Prostate Specific Antigen.

Zhang, X., T. G. Jin, H. Yang, W. C. DeWolf, R. Khosravi-Far, and A. F. Olumi. 2004. Persistent C-FLIP(L) Expression Is Necessary and Sufficient to Maintain Resistance to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Apoptosis in Prostate Cancer.

Halperin, T. J., S. A. Slavin, A. F. Olumi, and L. J. Borud. 2007. Surgical Management of Scrotal Lymphedema Using Local Flaps.

Li, W., X. Zhang, and A. F. Olumi. 2007. MG-132 Sensitizes TRAIL-Resistant Prostate Cancer Cells by Activating C-Fos/C-Jun Heterodimers and Repressing C-FLIP(L).

Zhang, L., X. Zhang, G. W. Barrisford, and A. F. Olumi. 2007. Lexatumumab (TRAIL-Receptor 2 MAb) Induces Expression of DR5 and Promotes Apoptosis in Primary and Metastatic Renal Cell Carcinoma in a Mouse Orthotopic Model.

Wang, Z., and A. F. Olumi. 2011. Diabetes, Growth Hormone-Insulin-Like Growth Factor Pathways and Association to Benign Prostatic Hyperplasia.

Aizer, A. A., J. J. Paly, A. L. Zietman, P. L. Nguyen, C. J. Beard, S. K. Rao, I. D. Kaplan, et al. 2012. Multidisciplinary Care and Pursuit of Active Surveillance in Low-Risk Prostate Cancer.